Zobrazeno 1 - 10
of 263
pro vyhledávání: '"E C Stein"'
Autor:
Yang, Xinyi1,2 (AUTHOR), Li, Jingyi1 (AUTHOR), Jiang, Xuchu1,3 (AUTHOR) xuchujiang@zuel.edu.cn
Publikováno v:
Scientific Reports. 11/16/2024, Vol. 14 Issue 1, p1-17. 17p.
Autor:
Papale, Anthony J.1 (AUTHOR) apapale@northwell.edu, Flattau, Robert2 (AUTHOR) rflattau@northwell.edu, Vithlani, Nandan2 (AUTHOR) nvithlani@northwell.edu, Mahajan, Deepti1 (AUTHOR), Nadella, Sandeep3,4 (AUTHOR) snadella@northwell.edu
Publikováno v:
Journal of Clinical Medicine. Nov2024, Vol. 13 Issue 22, p6948. 17p.
Autor:
Huang, Zirong1,2 (AUTHOR), Chen, Sheng3 (AUTHOR), Li, Xuechen1 (AUTHOR) xuechenl@hku.hk, Liu, Han1 (AUTHOR) liuhan@hku.hk
Publikováno v:
Chemistry - Methods. Aug2024, Vol. 4 Issue 7/8, p1-14. 14p.
Autor:
Tan, Chung Hong1 (AUTHOR), Low, Sze Shin2 (AUTHOR), Cheah, Wai Yan3 (AUTHOR), Singh, Jeevandeep4 (AUTHOR), Chai, Wai Siong5 (AUTHOR) wai‐siong.chai@nottingham.edu.cn, Tiong, Sieh Kiong1 (AUTHOR), Show, Pau Loke6 (AUTHOR) pauloke.show@ku.ac.ae
Publikováno v:
GCB Bioenergy. May2024, Vol. 16 Issue 5, p1-23. 23p.
Publikováno v:
Clinical pharmacology and therapeutics. 51(5)
Participants who completed up to week 190 in the long-term weight control study were monitored after cessation of medication between weeks 190 and 210. Caloric restriction, behavior modification sessions, exercise reinforcement, and physician visits
Publikováno v:
Clinical pharmacology and therapeutics. 51(5)
To assess continued efficacy of anorexiants after 3 years of use, 52 participants (43% of those starting) entered a second double-blind trial to compare 60 mg sustained-release fenfluramine plus 15 mg phentermine resin versus placebo added to behavio
Autor:
M, Weintraub, P R, Sundaresan, B, Schuster, G, Ginsberg, M, Madan, A, Balder, E C, Stein, L, Byrne
Publikováno v:
Clinical pharmacology and therapeutics. 51(5)
Between weeks 34 and 104, we explored different schema for administering fenfluramine plus phentermine in open-label fashion. At week 34, the original placebo group participants began taking fenfluramine plus phentermine (placebo-to-active group). Th
Publikováno v:
Clinical pharmacology and therapeutics. 51(5)
Between weeks 104 and 156 we attempted to optimize response by adjusting the doses of fenfluramine and phentermine. Dosing changes were based on an algorithm that aimed to achieve 120% of ideal body weight (IBW) while minimizing adverse effects. The
Autor:
Maqbool, Zahra1 (AUTHOR), Khalid, Waseem2 (AUTHOR) sania.zia@uifst.uol.edu.pk, Mahum3 (AUTHOR), Khan, Anosha4 (AUTHOR), Azmat, Maliha4 (AUTHOR), Sehrish, Aqeela5 (AUTHOR), Zia, Sania2 (AUTHOR) sania.zia@uifst.uol.edu.pk, Koraqi, Hyrije6 (AUTHOR), AL‐Farga, Ammar7 (AUTHOR), Aqlan, Faisal8 (AUTHOR) aqlanfaisal@gmail.com, Khan, Khalid Ali9,10 (AUTHOR)
Publikováno v:
Food Science & Nutrition. Feb2024, Vol. 12 Issue 2, p707-721. 15p.
Autor:
Audet J; Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Centre de recherche du Centre Hospitalier de l'Université de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada., Lecomte CG; Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Centre de recherche du Centre Hospitalier de l'Université de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada., Harnie J; Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Centre de recherche du Centre Hospitalier de l'Université de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada., Yassine S; Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Centre de recherche du Centre Hospitalier de l'Université de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada., Al Arab R; Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Centre de recherche du Centre Hospitalier de l'Université de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada., Soucy F; Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Centre de recherche du Centre Hospitalier de l'Université de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada., Morency C; Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Centre de recherche du Centre Hospitalier de l'Université de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada., Mari S; Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Centre de recherche du Centre Hospitalier de l'Université de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada., Jéhannin P; Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Centre de recherche du Centre Hospitalier de l'Université de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada., Merlet AN; Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Centre de recherche du Centre Hospitalier de l'Université de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada., Frigon A; Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Centre de recherche du Centre Hospitalier de l'Université de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
Publikováno v:
The Journal of physiology [J Physiol] 2024 Jan; Vol. 602 (1), pp. 183-204. Date of Electronic Publication: 2023 Nov 28.